Loading...
•
Mar 31
Reviva Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025
Key Takeaways
Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $6.1 million for the first quarter of 2025. The company's focus remains on advancing its late-stage brilaroxazine program.
Net loss for Q1 2025 was $6.1 million.
Research and development expenses were $4.7 million in Q1 2025.
General and administrative expenses were $1.4 million in Q1 2025.
The company had $2.3 million in cash and cash equivalents as of March 31, 2025.
Reviva
Reviva
Forward Guidance
Reviva Pharmaceuticals anticipates significant milestones for its brilaroxazine program, including reporting full data from the RECOVER OLE trial in Q2 2025 and initiating the registrational Phase 3 RECOVER-2 trial mid-2025. The company targets a potential New Drug Application (NDA) submission in Q4 2026.
Positive Outlook
- Full data set from RECOVER OLE trial expected in Q2 2025.
- Registrational Phase 3 RECOVER-2 trial initiation expected mid-2025.
- Targeting potential New Drug Application (NDA) submission for brilaroxazine in Q4 2026.
- Brilaroxazine program advancing towards registration.
- Brilaroxazine continues to demonstrate a differentiated and promising therapeutic profile.
Challenges Ahead
- No specific negative forward guidance points were mentioned in the report.
- No specific negative forward guidance points were mentioned in the report.
- No specific negative forward guidance points were mentioned in the report.
- No specific negative forward guidance points were mentioned in the report.
- No specific negative forward guidance points were mentioned in the report.